News stories about Novo Nordisk A/S (NYSE:NVO) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novo Nordisk A/S earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.6297585359734 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Novartis to Divest Portions of Sandoz US to Aurobindo (finance.yahoo.com)
- Novo Nordisk A/S (NVO) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised) (finance.yahoo.com)
- Novo Nordisk A/S (CPSE:NOVO B) Cash Flow Changes -0.08277 YoY (zeelandpress.com)
- Symphogen elects new Board members to support the Company’s long-term development (feeds.benzinga.com)
Shares of NVO stock traded up $0.02 on Friday, hitting $47.96. 726,500 shares of the stock were exchanged, compared to its average volume of 1,485,991. The stock has a market capitalization of $117.41 billion, a P/E ratio of 20.50, a P/E/G ratio of 2.59 and a beta of 0.65. Novo Nordisk A/S has a fifty-two week low of $44.28 and a fifty-two week high of $58.37.
Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 8th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.04. The company had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.33 billion. Novo Nordisk A/S had a return on equity of 83.32% and a net margin of 35.95%. sell-side analysts anticipate that Novo Nordisk A/S will post 2.52 earnings per share for the current fiscal year.
The company also recently disclosed a special dividend, which was paid on Tuesday, August 28th. Stockholders of record on Monday, August 20th were given a dividend of $0.4669 per share. The ex-dividend date of this dividend was Friday, August 17th. This represents a dividend yield of 1.72%. Novo Nordisk A/S’s dividend payout ratio is currently 27.78%.
Several research firms have recently weighed in on NVO. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, July 31st. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Monday, July 2nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus price target of $64.00.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Featured Story: Hedge Funds
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.